Online supplement to: Radiographic Progression Inhibition with Intravenous Golimumab in Psoriatic Arthritis: Week 24 Results of a Phase III, Randomized, Double-blind, Placebo-controlled Trial. *The Journal of Rheumatology*. doi:10.3899/jrheum.180681

ONLINE SUPPLEMENTARY DATA


SUPPLEMENTARY TABLE 1. Number (%) of patients with PIC or GO deformity at

baseline and Week 24 by reader (full analysis set for structural damage endpoints)

| | IV Placebo | IV Golimumab 2 |
|---|------------|----------------|
| | | mg/kg |
| Patients randomized, n | 239 | 241 |
| Patients with both baseline and Week 24 | 215 | 231 |
| evaluations | | |
| Reader 1 | | |
| PIC or GO at baseline | 8 (3.7) | 5 (2.2) |
| PIC or GO at Week 24 | 9 (4.2) | 5 (2.2) |
| Reader 2 | | |
| PIC or GO at baseline | 23 (10.7) | 20 (8.7) |
| PIC or GO at Week 24 | 24 (11.2) | 21 (9.1) |
| | | |

GO – gross osteolysis, PIC – pencil-in-cup

SUPPLEMENTARY FIGURE 1. Cumulative probability plots of changes in total PsA-modified SHS at week 24 (full analysis set for structural damage endpoints) for patients with (**A**) and without (**B**) NSAID use at baseline and for patients with (**C**) and without (**D**) oral low-dose corticosteroid use at baseline. NSAID - nonsteroidal anti-inflammatory drug, PsA - psoriatic arthritis, SDC - smallest detectable change, SHS - Sharp/van der Heijde Score Online supplement to: Radiographic Progression Inhibition with Intravenous Golimumab in Psoriatic Arthritis: Week 24 Results of a Phase III, Randomized, Double-blind, Placebo-controlled Trial. *The Journal of Rheumatology*. doi:10.3899/jrheum.180681



Placebo + Golimumab 2 mg/kg